Ovarian cancer treatment with a tumor-targeting and gene expression-controllable lipoplex

Scientific Reports

Volumn 6, Issue , 2016, Pages

  He, Zhi Yao ^a   Deng, Feng ^b   Wei, Xia Wei ^a   Ma, Cui Cui ^a   Luo, Min ^a   Zhang, Ping ^a   Sang, Ya Xiong ^a,b   Liang, Xiao ^a   Liu, Li ^a   Qin, Han Xiao ^a   Shen, Ya Li ^a   Liu, Ting ^a   Liu, Yan Tong ^a   Wang, Wei ^a   Wen, Yan Jun ^a   Zhao, Xia ^a,b   Zhang, Xiao Ning ^c   Qian, Zhi Yong ^a   Wei, Yu Quan ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

^c Tsinghua University   (China)

Author keywords

[No Author keywords available]

Indexed keywords

LIPOSOME; MATRIX PROTEIN;

ANIMAL; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; FEMALE; GENE THERAPY; GENETIC TRANSFECTION; GENETICS; HUMAN; NUDE MOUSE; OVARIAN NEOPLASMS; PATHOLOGY; PLASMID; TUMOR CELL LINE; VESICULOVIRUS;

ANIMALS; CELL LINE, TUMOR; FEMALE; GENETIC THERAPY; HUMANS; LIPOSOMES; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; OVARIAN NEOPLASMS; PLASMIDS; TRANSFECTION; VESICULOVIRUS; VIRAL MATRIX PROTEINS;

EID: 84962339493     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep23764     Document Type: Article

References (60)

1. Chornokur, G., Amankwah, E. K., Schildkraut, J. M. & Phelan, C. M. Global ovarian cancer health disparities. Gynecol Oncol 129, 258-264 (2013).
2. Jayson, G. C., Kohn, E. C., Kitchener, H. C. & Ledermann, J. A. Ovarian cancer. Lancet 384, 1376-1388 (2014).
3. Torre, L. A. et al. Global cancer statistics, 2012. CA Cancer J Clin 65, 87-108 (2015).
4. Flesken-Nikitin, A. et al. Ovarian surface epithelium at the junction area contains a cancer-prone stem cell niche. Nature 495, 241-245 (2013).
5. Liu, T. W. et al. Biologically-targeted detection of primary and micro-metastatic ovarian cancer. Theranostics 3, 420-427 (2013).
6. Vergote, I. et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 363, 943-953 (2010).
7. Bast, R. C., Jr., Hennessy, B. & Mills, G. B. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer 9, 415-428 (2009).
8. Lengyel, E. Ovarian cancer development and metastasis. Am J Pathol 177, 1053-1064 (2010).
9. Coleman, R. L., Monk, B. J., Sood, A. K. & Herzog, T. J. Latest research and treatment of advanced-stage epithelial ovarian cancer. Nat Rev Clin Oncol 10, 211-224 (2013).
10. Berns, E. M. J. J. & Bowtell, D. D. The changing view of high-grade serous ovarian cancer. Cancer Res 72, 2701-2704 (2012).
11. Katsumata, N. et al. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncol 14, 1020-1026 (2013).
12. Stark, D. et al. Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial. Lancet Oncol 14, 236-243 (2013).
13. Ledermann, J. et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 366, 1382-1392 (2012).
14. Farley, J. et al. Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, singlearm, phase 2 study. Lancet Oncol 14, 134-140 (2013).
15. Naumann, R. W. et al. PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer. J Clin Oncol 31, 4400-4406 (2013).
16. Bookman, M. A. et al. Better therapeutic trials in ovarian cancer. J Natl Cancer Inst 106, dju029 (2014).
17. Tait, D. L., Obermiller, P. S., Jensen, R. A. & Holt, J. T. Ovarian cancer gene therapy. Hematol Oncol Clin North Am 12, 539-552 (1998).
18. Zeimet, A. G. & Marth, C. Why did p53 gene therapy fail in ovarian cancer? Lancet Oncol 4, 415-422 (2003).
19. He, Z.-Y. et al. Folate-linked lipoplexes for short hairpin RNA targeting Claudin-3 delivery in ovarian cancer xenografts. J Control Release 172, 679-689 (2013).
20. Yin, H. et al. Non-viral vectors for gene-based therapy. Nat Rev Genet 15, 541-555 (2014).
21. Bojesen, S. E. et al. Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet 45, 371-384 (2013).
22. Mocellin, S., Pooley, K. A. & Nitti, D. Telomerase and the search for the end of cancer. Trends Mol Med 19, 125-133 (2013).
23. Xie, X. et al. A novel hTERT promoter-driven E1A therapeutic for ovarian cancer. Mol Cancer Ther 8, 2375-2382 (2009).
24. Zhao, J. M. et al. A promising cancer gene therapy agent based on the matrix protein of vesicular stomatitis virus. FASEB J 22, 4272-4280 (2008).
25. Zhong, Q. et al. Efficient inhibition of cisplatin-resistant human ovarian cancer growth and prolonged survival by gene transferred vesicular stomatitis virus matrix protein in nude mice. Ann Oncol 19, 1584-1591 (2008).
26. Gou, M. et al. Efficient inhibition of C-26 colon carcinoma by VSVMP gene delivered by biodegradable cationic nanogel derived from polyethyleneimine. ACS Nano 4, 5573-5584 (2010).
27. Luo, S. et al. Combination of vesicular stomatitis virus matrix protein gene therapy with low-dose cisplatin improves therapeutic efficacy against murine melonoma. Cancer Sci 110, 1219-1225 (2010).
28. Jing, X. M. et al. VSV-MP gene therapy strategy inhibits tumor growth in nude mice model of human lung adenocarcinoma. Cancer Gene Ther 19, 101-109 (2012).
29. Florinas, S., Kim, J., Nam, K., Janat-Amsbury, M. M. & Kim, S. W. Ultrasound-assisted siRNA delivery via arginine-grafted bioreducible polymer and microbubbles targeting VEGF for ovarian cancer treatment. J Control Release 183, 1-8 (2014).
30. Gandhi, N. S., Tekade, R. K. & Chougule, M. B. Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: current progress and advances. J Control Release 194, 238-256 (2014).
31. Wei, X. et al. Cationic nanocarriers induce cell necrosis through impairment of Na+/K+-ATPase and cause subsequent inflammatory response. Cell Res 25, 237-253 (2015).
32. Cheng, Z., Al Zaki, A., Hui, J. Z., Muzykantov, V. R. & Tsourkas, A. Multifunctional nanoparticles: Cost versus benefit of adding targeting and imaging capabilities. Science 338, 903-910 (2012).
33. van Dam, G. M. et al. Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-alpha targeting: first in-human results. Nat Med 17, 1315-1319 (2011).
34. Kobel, M. et al. Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study. Br J Cancer 111, 2297-2307 (2014).
35. Srinivasarao, M., Galliford, C. V. & Low, P. S. Principles in the design of ligand-targeted cancer therapeutics and imaging agents. Nat Rev Drug Discov 14, 203-219 (2015).
36. Dadashzadeh, S., Mirahmadi, N., Babaei, M. H. & Vali, A. M. Peritoneal retention of liposomes: Effects of lipid composition, PEG coating and liposome charge. J Control Release 148, 177-186 (2010).
37. Lanuti, M. et al. Cationic lipid:bacterial DNA complexes elicit adaptive cellular immunity in murine intraperitoneal tumor models. Cancer Res 60, 2955-2963 (2000).
38. Kullberg, M., McCarthy, R. & Anchordoquy, T. J. Systemic tumor-specific gene delivery. J Control Release 172, 730-736 (2013).
39. Biswas, S. & Torchilin, V. P. Nanopreparations for organelle-specific delivery in cancer. Adv Drug Deliv Rev 66, 26-41 (2014).
40. Akita, H. et al. A neutral lipid envelope-type nanoparticle composed of a pH-activated and vitamin E-scaffold lipid-like material as a platform for a gene carrier targeting renal cell carcinoma. J Control Release 200, 97-105 (2015).
41. Ammayappan, A., Nace, R., Peng, K. W. & Russell, S. J. Neuroattenuation of vesicular stomatitis virus through picornaviral internal ribosome entry sites. J Virol 87, 3217-3228 (2013).
42. Muik, A. et al. Re-engineering vesicular stomatitis virus to abrogate neurotoxicity, circumvent humoral immunity, and enhance oncolytic potency. Cancer Res 74, 3567-3578 (2014).
43. Lin, X. et al. Efficient inhibition of intraperitoneal human ovarian cancer growth and prolonged survival by gene transfer of vesicular stomatitis virus matrix protein in nude mice. Gynecol Oncol 104, 540-546 (2007).
44. Du, X. B. et al. Vesicular stomatitis virus matrix protein gene enhances the antitumor effects of radiation via induction of apoptosis. Apoptosis 13, 1205-1214 (2008).
45. Wongthida, P. et al. Activating systemic T-cell immunity against self tumor antigens to support oncolytic virotherapy with vesicular stomatitis virus. Hum Gene Ther 22, 1343-1353 (2011).
46. Wu, K. J. et al. Direct activation of TERT transcription by c-MYC. Nat Genet 21, 220-224 (1999).
47. Kyo, S. et al. Sp1 cooperates with c-Myc to activate transcription of the human telomerase reverse transcriptase gene (hTERT). Nucleic Acids Res 28, 669-677 (2000).
48. McMurray, H. R. & McCance, D. J. Human papillomavirus type 16 E6 activates TERT gene transcription through induction of c-Myc and release of USF-mediated repression. J Virol 77, 9852-9861 (2003).
49. Zhao, Y., Cheng, D., Wang, S. & Zhu, J. Dual roles of c-Myc in the regulation of hTERT gene. Nucleic Acids Res 42, 10385-10398 (2014).
50. Zhang, P. et al. Gene therapy using the human telomerase catalytic subunit gene promoter enables targeting of the therapeutic effects of vesicular stomatitis virus matrix protein against human lung adenocarcinoma. Exp Ther Med 4, 859-864 (2012).
51. Charles River Laboratories International, Inc. BALB/c nude mouse biochemistry. Technical report. (2012) Available at http://www. criver.com/files/pdfs/rms/balbc-nude/rm-rm-r-balb-c-nude-mouse-clinical-pathology-data.aspx. (Accessed: 31th October 2015).
52. Tancevski, I. et al. Reduced plasma high-density lipoprotein cholesterol in hyperthyroid mice coincides with decreased hepatic adenosine 5' -triphosphate-binding cassette transporter 1 expression. Endocrinology 149, 3708-3712 (2008).
53. Carrion, J. et al. Microbial carriage state of peripheral blood dendritic cells (DCs) in chronic periodontitis influences DC differentiation, atherogenic potential. J Immunol 189, 3178-3187 (2012).
54. Snelgrove, R. J. et al. Alternaria-derived serine protease activity drives IL-33-mediated asthma exacerbations. J Allergy Clin Immunol 134, 583-592.e6 (2014).
55. He, Z. et al. Gene delivery with active targeting to ovarian cancer cells mediated by folate receptor α . J Biomed Nanotechnol 9, 833-844 (2013).
56. Li, J. et al. Micelles based on methoxy poly(ethylene glycol) cholesterol conjugate for controlled and targeted drug delivery of a poorly water soluble drug. J Biomed Nanotechnol 8, 809-817 (2012).
57. Shi, W. et al. Antitumor and antimetastatic activities of vesicular stomatitis virus matrix protein in a murine model of breast cancer. J Mol Med 87, 493-506 (2009).
58. Han, H. D. et al. Targeted gene silencing using RGD-labeled chitosan nanoparticles. Clin Cancer Res 16, 3910-3922 (2010).
59. Wen, Y. et al. Immunotherapy targeting folate receptor induces cell death associated with autophagy in ovarian cancer. Clin Cancer Res 21, 448-459 (2015).
60. Apte, S. M., Fan, D., Killion, J. J. & Fidler, I. J. Targeting the platelet-derived growth factor receptor in antivascular therapy for human ovarian carcinoma. Clin Cancer Res 10, 897-908 (2004).